Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 41

Results For "Clinical"

3359 News Found

Bayer wins world-first nod in Japan for low-dose MRI contrast agent
News | March 24, 2026

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging


Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
Clinical Trials | March 24, 2026

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

The company plans to submit the vaccine for regulatory review


Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
Clinical Trials | March 24, 2026

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials


Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
News | March 23, 2026

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety


Godavari Biorefineries secures Japanese patent for antiviral compounds
R&D | March 23, 2026

Godavari Biorefineries secures Japanese patent for antiviral compounds

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways


Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026
R&D | March 23, 2026

Altesa BioSciences unveils breakthrough data on Rhinovirus Drug at ICAR2026

Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses


TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial
News | March 23, 2026

TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial

The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611


AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051
Clinical Trials | March 23, 2026

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention


Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer
Clinical Trials | March 21, 2026

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival